Your Migraine Days Could Cut By Half With This Common FDA‑Approved Diabetes Injection, Study Finds

Migraines have been the bane of millions—debilitating, unpredictable, and extremely difficult to treat but a new challenger has entered the fray: a group of medications that have become synonymous with weight loss. Recent studies indicate that GLP-1 receptor agonists medications such as liraglutide, widely prescribed for the treatment of type 2 diabetes and obesity could radically cut migraine frequency, giving fresh hope to sufferers.New research, presented at the European Academy of Neurology (EAN) Congress 2025, may herald a new era in neurological care by re-purposing a currently available medication for a new, impactful application.GLP-1 receptor agonists such as liraglutide, Ozempic, and Wegovy replicate the body's natural hormone glucagon-like peptide-1, which is crucial in maintaining blood sugar levels, hunger, and digestion. These medications are widely used to treat diabetes and help achieve long-term weight loss. However, more and more, their influences on the nervous system and intracranial pressure are capturing neurologists' attention.In their research, scientists investigated whether GLP-1 medications could alleviate migraines not by causing weight loss, but through another mechanism by lowering pressure in the cerebrospinal fluid, a lesser-known migraine attack factor.The pilot study, conducted by Dr. Simone Braca and his team at the Headache Centre, University of Naples, included 26 adults with chronic or frequent migraines who were obese. The subjects took daily doses of 1.8 mg liraglutide, the standard dose employed to treat type 2 diabetes, for 12 weeks.The study findings were remarkable, volunteers saw their average monthly headache days plummet dramatically from 20 to just 9. Almost half of the participants reported at least a 50% decrease in frequency of migraines, which makes the drug a potential breakthrough medication. Besides fewer migraines, volunteers also reported improved daily functioning, work productivity, and social activity. Although mild side effects including nausea and constipation were noted, no participants dropped out of the treatment, highlighting the drug's overall tolerability.Even more persuasively, researchers pointed out that weight loss was modest and statistically not significant meaning that the relief from migraine could not be attributed to losing weight but may be associated with deeper neurological mechanisms.May Pressure Be the Secret Trigger?One of the central hypotheses to which the researchers give consideration relates to intracranial pressure. Migraine patients tend to exhibit elevated cerebrospinal fluid pressure, which can irritate brain structures and intensify headaches. Liraglutide, as with other GLP-1 agonists, seems to slow CSF secretion, thus possibly relieving pressure within the skull.Though the precise mechanism remains under investigation, this hypothesis is upheld by previous research indicating that GLP-1 medications were beneficial in treating idiopathic intracranial hypertension (IIH), an uncommon disorder characterized by increased pressure in the brain.In order to separate migraines from IIH in this research, subjects were screened to rule out individuals with papilledema (swelling of the optic disc) and sixth nerve palsy, both signs of increased intracranial pressure.What This Means for People Who Experience Migraine?The idea of drug repurposing—identifying new applications for existing drugs—is catching on in medicine. Because liraglutide is already approved and heavily prescribed to treat diabetes and obesity, its migraine-reducing potential may accelerate its transition for this new purpose."The improvement persisted throughout the entire three-month observation time, despite modest weight loss," said lead study author Dr. Braca. "The majority of patients improved within the first two weeks."Since migraines afflict more than 6 million individuals in the UK alone, and millions worldwide, an easily tolerated, easily accessible drug which could cut their number by almost half is a major advancement.Migraine is more than just a headache—it's a neurological disorder with severe consequences for everyday life. Attacks can persist for 72 hours, involving pounding pain, nausea, vomiting, dizziness, and increased sensitivity to light, sound, and odour. Chronic migraine, being 15 or more headache days in a month, impacts work productivity, mental health, and quality of life.For some, traditional treatments like triptans, anti-seizure drugs, and injections of Botox don't work or are accompanied by significant side effects. A new group of therapy that treats migraines by a different process might extend the field of available options to millions of patients.How It Affects To Long-Term Applications?Although the pilot study presents encouraging findings, scientists advise that larger randomized controlled trials should be conducted. Future studies will include direct measurement of intracranial pressure and investigate whether other GLP-1 medications, possibly with reduced gastrointestinal side effects, could yield similar findings.We're just scratching the surface of what these drugs can do," Dr. Roberto De Simone, a team member senior to many, said. "We're optimistic that this might unlock a new avenue in treating not only migraines, but even other neurologically-related conditions.Already, GLP-1 drugs are in the pipelines as potential treatments for stroke risk reduction, Alzheimer's disease, and even addiction—implying their therapeutic scope may be much wider than initially believed.For decades, migraine patients have tried in vain to find relief. With this new study, a familiar medication could soon provide an unsuspecting answer. If subsequent studies validate the research, GLP-1 receptor agonists such as liraglutide could revolutionize migraine treatment—giving patients not only fewer headache days, but improved lives.

Your Migraine Days Could Cut By Half With This Common FDA‑Approved Diabetes Injection, Study Finds

Quick Stories

FDA Approves Once-Monthly Injection For Hereditary Angioedema; What It Means For Long-Term Treatment?

Popular Contacts Lens Brand Issues Urgent Recall After Reports Of 'Visual Disturbances'; What’s Causes Len's Related-Eye Irritation?

Legionnaires' Disease Outbreak In Sydney—One Dead, Dozens Exposed: What You Need To Know And How It Spreads?

Health Conditions A-Z

FDA Approves Once-Monthly Injection For Hereditary Angioedema; What It Means For Long-Term Treatment?

'Grateful For Second Life', Says Ankur Warikoo As He Shares His Fitness Journey With His Followers

You’re Most Likely To Live Next To A Psychopath In These US States